Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB by Wang, Cun-Yu et al.
412 NATURE MEDICINE • VOLUME 5 • NUMBER 4 • APRIL 1999
ARTICLES
Resistance of tumors and hematological neoplasms to chemothera-
pies is a common clinical problem in human cancer1. Resistance to
chemotherapies may already exist before the initiation of therapy
because of overexpression of the multidrug resistance gene product
MDR1, which functions to export a variety of chemotherapies from
tumor cells2. Moreover, chemoresistance (acquired or inducible)
may develop in response to chemotherapy by mostly unknown
mechanisms. Apoptosis (programmed cell death) seems to be the
main mechanism whereby chemotherapy and radiation induce the
killing of tumor cells1,3–5. Apoptosis also serves as a cell-killing
mechanism induced by cytokines such as tumor necrosis factor a
(TNFa ) (ref. 6). Apoptosis induced by TNFa and by chemotherapy
and radiation seem to require, at least partially, the activation of
the caspase cascade, leading to proteolytic cleavage of a variety of
important proteins and ultimately to cleavage of cellular DNA (refs.
4,6,7). TNFa , chemotherapy, radiation and other stimuli activate
the transcription factor NF-k B, and this response potently sup-
presses the apoptotic potential of these stimuli in vitro8–12. Here we
analyzed the effect of inhibition of NF- k B in parallel with TNFa or
chemotherapy treatment on experimental tumors. Our data estab-
lish that the inhibition of NF-k B activation in tumors through the
adenoviral delivery of a modified form of I k Ba , the natural in-
hibitor of NF-k B (refs. 13,14), functions to substantially enhance
the apoptotic potential of cancer therapies. Thus, NF-k B activation
serves as a principal mechanism for inducible resistance to
chemotherapy, and inhibition of NF-k B could be a new adjuvant
approach for cancer treatment.
TNF a elicits tumor regression after NF- k B inhibition
Although TNFa can elicit apoptosis in some tumor cells in vitro
and in some experimental tumor models, limited responses are
obtained with systemic delivery of TNFa because of toxicity and
resistance of tumor cells to induced cell death15. TNFa has shown
efficacy in combination with interferon- g against some sarcomas
and melanomas, using limb perfusion approaches16. TNFa disrupts
tumor vasculature endothelium17 through reduction of expression
of a Vb 3 integrin18, but does not have a direct killing effect on
tumor cells. TNFa can elicit apoptosis in cell culture if NF-k B is in-
hibited8–11; thus, we sought to determine if similar results could be
attained in tumors in vivo. We generated in nude mice fibrosar-
coma tumors derived from HT1080 cells with an empty expression
vector (HT1080V) or HT1080 cells expressing a modified form of
the NF-k B inhibitor Ik Ba (HT1080I cells; ref. 8). The modification
of Ik Ba blocks its ability to be phosphorylated and to be subse-
quently degraded, thereby preventing NF-k B translocation to the
nucleus19. HT1080I cells are blocked in their ability to activate NF-
k B (ref. 8). Intratumoral injection of TNFa yields enhanced anti-
tumor effects compared with systemic treatment15 and systemic
delivery of high levels of TNFa is toxic in mice (data not shown).
Thus, we assessed the anti-tumor effects after intratumoral admin-
istration of TNFa in HT1080V and HT1080I tumors of similar size.
HT1080I tumors grow more slowly than HT1080V tumors. The
HT1080I tumor mass was eradicated within 7 days, leaving only
scar tissue after TNFa treatment (Fig. 1). Most HT1080I tumors (17
of 20) were eradicated by TNFa , whereas only a few HT1080V tu-
mors (3 of 20) regressed, presumably because of the effect of TNFa
on tumor vasculature.
TNF a induces tumor apoptosis when NF- k B is inhibited
TNF a causes ‘hemorrhagic necrosis’ of tumors through effects
on tumor vasculature17,18; thus, we determined whether the ef-
fect of TNF a on HT1080I tumors was through apoptotic or
necrotic mechanisms. We collected several HT1080V and
HT1080I tumors after 16–24 hours of TNF a treatment and ana-
lyzed the samples by TUNEL assay (Fig. 2a–d), which detects
DNA fragmentation and is commonly used to detect apoptosis.
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Programmed cell death (apoptosis) seems to be the principal mechanism whereby anti-onco-
genic therapies such as chemotherapy and radiation effect their responses. Resistance to apop-
tosis, therefore, is probably a principal mechanism whereby tumors are able to overcome these
cancer therapies. The transcription factor NF- k B is activated by chemotherapy and by irradiation
in some cancer cell lines. Furthermore, inhibition of NF- k B in vitro leads to enhanced apoptosis in
response to a variety of different stimuli. We show here that inhibition of NF-k B through the
adenoviral delivery of a modified form of I k B a , the inhibitor of NF- k B, sensitizes chemoresistant
tumors to the apoptotic potential of TNFa and of the chemotherapeutic compound CPT-11, re-
sulting in tumor regression. These results demonstrate that the activation of NF-k B in response
to chemotherapy is a principal mechanism of inducible tumor chemoresistance, and establish
the inhibition of NF- k B as a new approach to adjuvant therapy in cancer treatment.
© 1999 Nature America Inc. • http://medicine.nature.com
© 
19
99
 N
at
ur
e 
Am
er
ic
a 
In
c.
 • 
ht
tp
://
m
ed
ic
in
e.
na
tu
re
.c
om
NATURE MEDICINE • VOLUME 5 • NUMBER 4 • APRIL 1999 413
ARTICLES 
Fig. 1 TNFa induces tumor re-
gression when NF-k B activation is
blocked. HT1080V or HT1080I tu-
mors were grown to similar size in
nude mice. TNFa was injected in-
tratumorally once a day for 3 d
and mice were photographed 7 d
after the final TNFa injection. Left,
mouse with two HT1080I tumors
(expressing the ‘super-repressor’
form of Ik Ba ); right, mouse with
two HT1080V tumors. Tumors re-
sponding with complete regres-
sion: I (HT1080I), 17 of 20 ; V
(HT1080V), 3 of 20.
HT1080I tumors had widespread TUNEL-positive cells, in con-
trast to the staining of HT1080V tumors (Fig. 2d), indicating
that TNF a elicited tumor cell apoptosis when NF- k B was inhib-
ited. To confirm that TNF a caused tumor regression, we col-
lected the tumor and surrounding soft tissue and examined
their histology (Fig 2e–h). The HT1080I tumor treated with TNF
regressed and was replaced by scar tissue consisting mainly of fi-
broblasts (Fig. 2h). There was some regression of the HT1080V
tumor in response to TNF (Fig. 2g). Although the central por-
tion of the tumor mass was destroyed, a peripheral rim of appar-
ently viable tumor tissue was spared (data not shown).
Although we have no direct data on this, our result is consistent
with reports showing that TNF a disrupts tumor microvascula-
ture, leading to tumor necrosis17,18.
Potentiation of chemotherapy-induced cell death in vitro
To explore gene therapy approaches relevant to the inhibition of
NF- k B, we used cDNA encoding the ‘super-repressor’ form of
I k B a (ref. 19) cloned into an adenovirus 5 vector to produce
replication-defective Ad.CMV.I k B a (ref. 20). To determine if the
virus was effective in inhibiting NF-k B, we infected HT1080 cells
with the control adenovirus Ad.CMV3 or with Ad.CMV.Ik B a
and treated these cells with TNFa . Ad.CMV.I k B a, but not the
control virus, blocked NF-k B induction and led to considerable
cell death in the TNFa -treated cells (data not shown). Next, we
determined whether the Ik B a -encoding virus would enhance
apoptosis in HT1080 tumors in response to TNFa . Systemic de-
livery of TNF a in combination with the intratumoral injection of
either control Ad.CMV3 or Ad.CMV.Ik B a produced lethal toxic-
ity in the mice (data not shown). We therefore focused on en-
hancing chemotherapeutic responses in tumors.
The chemotherapeutic compound camptothecin (CPT), a
topoisomerase I inhibitor, is effective against a variety of tu-
mors21. Consistent with reports on topoisomerase inhibitors and
other chemotherapies8,22–24, we found that camptothecin po-
tently activated NF- k B in the HT1080 fibrosarcoma cells (Fig. 3a).
NF- k B activation reached a maximum after 2 hours and was sus-
tained in the nucleus after 7 hours. CPT-11, an analog of camp-
tothecin, has broad anti-tumor function, and is one of the most
promising anticancer drugs now in clinical trials25. The active
metabolite of CPT-11, SN38, is responsible for anti-tumor activ-
ity in vivo26. Therefore, we determined whether SN38 activated
NF- k B. SN38 induced nuclear translocation of NF-k B in a dose-
dependent manner and at a concentration as low as 0.1 m M (Fig.
3b). The induced NF-k B was a classical heterodimer with a 50-
kDa subunit and a 65-kDa subunit, as confirmed by antibody ‘su-
pershift’ analysis with p50 and p65 antibodies (Fig. 3c). Our p50
antibody is ineffective in ‘supershifting’ a p50–p65 heterodimer.
To determine whether the activation of NF-k B had an effect on
CPT- and SN38-induced cytotoxicity, we treated HT1080V or
HT1080I cells with CPT or SN38 for 24 hours. The cytotoxicity
generated by CPT or SN38 was enhanced considerably by inacti-
vation of NF- k B, although less so at the lower concentrations of
drug (Fig. 3d).
Enhanced CPT-11-mediated apoptosis and tumor regression
To determine if the inhibition of NF-k B would enhance anti-
tumor responses of CPT-11, we established HT1080 tumors by
subcutaneous injection of cells in nude mice. We injected tu-
mors with either control virus (Ad.CMV3), the adenovirus en-
coding the ‘super-repressor’ form of Ik B a (Ad.CMV.I k B a ) or
vehicle alone. We then treated mice systemically with either
CPT-11 or with PBS and measured tumor volume for 20 days.
Neither CPT-11 alone nor Ad.CMV.I k B a alone resulted in inhibi-
tion of tumor growth (Fig. 4). There was enhanced fibrosarcoma
growth in the presence of chemotherapy alone. However, com-
bined systemic CPT-11 treatment and tumor injection with
V=HT1080V I=HT1080I I=HT1080IV=HT1080V
–TNF
+TNF
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Fig. 2 Tumor regression induced by TNFa in NF- k B inhibited cells is due
to apoptosis. HT1080V and HT1080I tumors were injected intratumorally
with TNF a once a day for 3 d. a–d, Measurement of apoptosis in HT1080V
or HT1080I tumors after 16–24 h of TNFa treatment, shown by TUNEL
staining. Apoptosis is widespread in the HT1080I tumor injected with TNF a
(d) but not in untreated HT1080I tumor (b) or in HT1080V treated (c) or un-
treated (a). e–h, Histology of the tumors. HT1080V and HT1080I tumors
were collected 2 weeks after TNFa treatment. The HT1080I tumor treated
with TNF a (h) regressed and was replaced by scar tissue, whereas the
HT1080V tumor not treated with TNF a (g) continued to grow.
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Fig. 3 Activation of NF-k B in human fibrosarcoma cells by CPT and
SN38. a, Kinetics of activation of NF-k B by CPT. HT1080V and
HT1080I cells were treated with 5 m M CPT for 0.5, 2 and 7 h. Nuclear
extracts were analyzed by EMSA. Arrow, NF-k B mobility. b, Activation
of NF-k B in fibrosarcoma cells by SN38, the active metabolite of CPT-
11. HT1080V and HT1080I cells were treated with SN38 (concentra-
tions in m M below blot) for 2 h. c, Subunit composition of NF-k B
activated by CPT or SN38. Nuclear extracts from CPT-treated or SN38
treated cells were pre-incubated with antibodies to the p50 and 65
subunits followed by EMSA. Arrows, mobilities of NF-k B and ‘super-
shifted’ complexes. d, Inhibition of NF-k B leads to enhanced cell
death in response to CPT (left) or SN38 (right). HT1080V and HT1080I
cells were treated with CPT or SN38 (concentrations in m M below
graphs) for 24 h; surviving cells were identified by crystal violet assay
(vertical axis; as % of surviving cells).
Ad.CMV.I k B a (but not Ad.CMV3) elicited significant inhibition
of tumor growth (Fig. 4). Furthermore, inhibition of tumor cell
growth in vitro with combined chemotherapy and inhibition of
NF- k B was attained with tumor cell lines expressing either wild-
type or mutant p53, although the presence of wild-type p53
seemed to enhance the cell death response (J.C.C., R.L. and
A.S.B., unpublished data).
To determine if the anti-tumor effect was elicited by apoptosis,
we isolated tumors 48 hours after the initial viral treatment and
24 hours after the initial CPT-11 treatment and sectioned them
for histology and TUNEL assays. CPT-11 treatment plus inhibi-
tion of NF- k B led to tumors with mostly apoptotic cells (Fig. 5).
Treatment with CPT-11 alone or with Ad.CMV.Ik B a alone
yielded almost no apoptotic responses in the tumors. Moreover,
NF- k B was activated in the tumors treated with CPT-11 and this
activation was suppressed by expression of Ik B a (J.C.C, R.L. and
A.S.B., unpublished data).
To determine if this enhanced anti-tumor response could be
attained in other tumor models, we explored the use of
Ad.CMV.I k B a in combination with CPT-11 in the Lovo colorec-
tal tumor model. CPT-11 and Ad.CMV.Ik B a in combination led
to considerable suppression of tumor growth associated with a
substantially enhanced apoptotic response, whereas CPT-11 or
Ad.CMV.I k B a alone were ineffective at inducing these responses
(Table). These results show that CPT-11 was unable to elicit an
apoptotic response in fibrosarcoma or colorectal tumors unless
NF- k B was inhibited, establishing NF-k B as a principal mediator
of inducible chemoresistance.
Discussion
Many cancer cells either show chemo- or radioresistance or ac-
quire resistance after therapy27,28. Increased concentrations of cy-
totoxic drugs and higher dosages of irradiation fail to improve
the pharmacotherapeutic response in resistant cancer cells.
Thus, research efforts are aimed at determining the regulatory
events involved in chemo- and radioresistance. Resistance to
apoptosis controls the ability of tumors to withstand high levels
of chemotherapy and radiation1. Moreover, cells that are resis-
tant to apoptosis seem to have a growth advantage in tumors29,30.
Therefore, the development of approaches to lower the apop-
totic threshold within tumor cells is likely to prove useful both
as a direct cancer treatment and in combination with radiation
and chemotherapy.
Resistance to cancer chemotherapy can be caused in many
ways. One mechanism of chemoresistance is caused by overex-
pression of MDR1, a transmembrane protein that functions to
export chemotherapeutic compounds from cells2. Another
mechanism seems to be inducible or acquired resistance of the
tumor to apoptosis, which blocks the ability of chemotherapies
and radiation to induce tumor cell death2. Acquired resistance
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Fig. 4 Fibrosarcoma tumor growth inhibition in response to CPT-11 treat-
ment and inhibition of NF-k B. HT1080 xenografts were injected intratu-
morally with Ad.CMV.I k B a . Mice received CPT-11 intravenously 24 h later,
then every 4 d (for five dosages). Virus was injected again 7 days after the
first virus injection. Ad.CMV3 and vehicle alone, vector controls; PBS, drug
treatment control. Tumor volume ( vertical axis) represents mean – s.e.m.
(n = 12–16 per group) of one of two experiments. Tumor growth after com-
bined treatment with the ‘super-repressor’ Ik B a and CPT-11 was signifi-
cantly less at day 20 than growth after treatment with either reagent alone
(P < 0.001, ANOVA).
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may result from mutations in p53 or overexpression of anti-
apoptotic proteins such as Bcl-2. Although there may be many
mechanisms by which resistance to apoptosis is achieved in tu-
mors, our data indicate that a main pathway involved in in-
ducible resistance is the activation of the transcription factor
NF- k B within tumor cells in response to chemotherapy or TNF a .
In either case, inhibition of cancer therapy-induced NF-k B acti-
vation strongly enhances the apoptotic potential of these stim-
uli. Our findings probably explain the lack of efficacy of TNF a in
cancer trials15,16 and the reduced efficacy of chemotherapies in
general1 and identify an important mechanism whereby tumors
are induced to become resistant to cancer therapy. Consistent
with our results, the use of combined approaches in cancer ther-
apies has been described31–33, and it is much more efficacious
than a single type of treatment.
How does NF- k B activation suppress apoptosis in
tumor cells in response to TNF a or chemotherapy?
Because the ability of TNFa to elicit an apoptotic
response typically requires the inhibition of pro-
tein synthesis34, activation of NF- k B was assumed
to induce transcription of genes that encode gene
products that function to feedback and block apop-
tosis. Consistent with this, four gene products
(TRAF1 and 2 and c-IAP1 and 2) are upregulated by
NF- k B at the mRNA level that block the ability of
TNF a to activate the apical caspase, caspase-8 (ref.
35). Like TNF a , chemotherapy induces apoptosis
through induction of the caspase cascade. c-IAP1
and 2 expression alone can suppress etoposide-in-
duced apoptosis35, consistent with the ability of
these proteins to block activation of the downstream caspases,
caspase-3 and -7 (ref. 36). Apoptosis induced by chemotherapy
seems to involve the upregulation of Fas ligand and induced cell
killing controlled by Fas, at least in some cell types3. At present, it
is not known whether the activation of NF- k B suppresses Fas-me-
diated cell killing and, if so, whether the same NF-k B-regulated
gene products that suppress TNFa -induced apoptosis can sup-
press Fas-induced apoptosis. Although p53 is involved in apop-
tosis induced by chemotherapy and radiation5, our preliminary
data (unpublished) indicate that the enhanced apoptosis result-
ing from the combination of NF-k B inhibition and chemother-
apy treatment is at least partially p53-independent. This is
consistent with observations that oncogenic Ras induces apopto-
sis in a p53-independent manner when NF- k B is inhibited37.
Our results with TNFa and camptothecins provide a concep-
tual basis for improving the efficacy of chemotherapy and bio-
logic-based anti-cancer therapy. The main target for TNFa in
clinical cancer trials is the tumor microvasculature17,18. Our stud-
ies indicate that TNFa in parallel with NF- k B inhibition leads to
direct tumor cell killing. At present, it is unclear whether this
combined approach would augment or suppress the TNF a effect
on disruption of microvasculature. Combined cancer treatment
strategies that use inhibition of NF-k B may substantially aug-
ment the sensitivity of chemoresistant tumors and improve the
clinical response rates in these tumors. For neoplasms that show
chemosensitivity, the combined strategy may lower the level of
chemotherapy needed to effectively elicit an anti-cancer re-
sponse. Given the results of studies with two tumor model sys-
tems and with a variety of tumor cell lines and chemotherapies,
our results may be applicable to diverse tumors. However, we
cannot rule out the possibility that certain tumors or certain
chemotherapies may require NF- k B for inducing cell death.
The apoptotic response elicited in the tumors by CPT-11 and
Ad.CMV.I k B a injection is widespread. In fact, experimental con-
ditions can be modified so that near-complete tumor regression
is obtained by this approach (J.C.C, R.L. and A.S.B., unpublished
data). LacZ staining after injection of HT1080 tumors with
Ad.LacZ indicates that approximately 50% of tumor cells express
Fig. 5 Induction of apoptosis by CPT-11 and inhibition of NF-k B in HT1080
fibrosarcoma tumors. HT1080 tumors were injected intratumorally with
Ad.CMV.Ik Ba (a,b,g, and h), Ad.CMV3 (control vector; c and d) or PBS (ve-
hicle; e and f), then mice received an intravenous injection of CPT-11 (a–d)
or PBS (vehicle; e–h) 24 h later. Tumors were collected 48 h after initial treat-
ment (virus or PBS). Staining and original magnifications: a,c,e, and g, fluo-
rescent TUNEL assay, · 10; b,d,f and h, hematoxylin and eosin, · 40.
a b
c d
e f
g h
Table Tumoricidal response to combination CPT-11 and the super-repressor
I k B a in Lovo xenografts
Treatment group Tumor growth SR-Ik B a transgene Apoptotic scorec
responsea (cm3) expressionb
PBS/PBS 3.92 none +
Ad.CMV3/PBS 2.09 none +
PBS/CPT-11 2.88 none +
Ad.CMV3/CPT-11 2.12 none +
Ad.CMV.I k B a /CPT-11 0.43 ++++ ++++
Ad.CMV.I k B a /PBS 2.58 ++++ +
Tumors were injected with virus or PBS, then mice were injected with CPT-11 or PBS 24 h later. +, 0–25%
positive; ++, 26–50% positive; +++, 51–75% positive; and ++++, 76–100% positive. aThe growth re-
sponse ratio was calculated as the mean tumor volume on day 8 after treatment with CPT-11 or PBS (con-
trol). bSuper-repressor-I k B a transgene expression measured as the percentage of cells stained positive for
the hemagluttinin-tagged epitope on the supre-repressor I k B a protein. cApoptotic score measured as the
percentage of cells stained TUNEL-positive 24h after treatment.
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detectable levels of b -galactosidase. Therefore, either the inhibi-
tion of NF- k B in a subset of cells leads to bystander tumor cell
death, or the level of infection with the virus is near 100% and
the use of LacZ as a marker for gene transduction underestimates
the number of cells that actually express the modified form of
I k B a . Consistent with the latter, I k B a expression can be detected
in greater than 75% of cells in tumors injected with
Ad.CMV.I k B a . Whatever the mechanism, the data indicate that
effective mechanisms to suppress NF- k B activation should be de-
veloped and used to lower the apoptotic threshold as an adju-
vant approach for cancer chemotherapy. Successful efforts in the
gene therapy of tumors33,38–41 and in the development of small
molecule inhibitors of NF-k B (ref. 42) provide a logical basis for
an adjuvant approach in cancer therapy to inhibit NF- k B and its
associated anti-apoptotic function.
Methods
Cell cultures and adenovirus production. Stably transfected HT1080I cells
were made as described8. HT1080V, HT1080I and Lovo cells were cultured
in EMEM medium supplemented with 10% FCS, 100 m g/ml penicillin and
streptomycin and 200 m g/ml hygromycin (for HT1080V and HT1080I). The
control virus Ad.CMV3 was a gift from J. Roth (Houston, Texas)
Recombinant adenovirus (either control or expressing the ‘super-repressor’
form of I k B a ; ref. 20) was prepared by the University of North Carolina
Gene Therapy Center. The preparations of recombinant virus were shown
to contain less than 1–5 wild-type adenovirus per 106 virus.
Electrophoretic mobility shift assay (EMSA). Cell nuclear extracts (5–10
m g) were preincubated with 1 m g of poly (dI-dC) in binding buffer (10 mM
Tris, 50 mM NaCl, 20% glycerol, 1 mM DTT and 0.5 mM EDTA) for 10 min
at room temperature. Approximately 20,000 cpm of 32P-labeled DNA probe
containing the class I MHC NF- k B site was then added and allowed to bind
for 15 min. The complexes were separated by 5 % polyacrylamide gel elec-
trophoresis and detected by autoradiography.
Histology and deoxynucleotidyl transferase-mediated dUTP nick end
labeling (TUNEL) assay. Animals were killed by asphyxiation in a CO2
chamber. The tumors or scar tissues were fixed in 4% paraformaldehyde at
room temperature for 24 h. The specimens were cut into sections 4 m m in
thickness and stained with hematoxylin and eosin. For TUNEL staining, the
tumors were either untreated or treated intratumorally with TNF a for 16 h.
The tumors then were collected, embedded in OCT compound (Sakura,
Tokyo, Japan) and ‘snap frozen’ in liquid nitrogen. Frozen sections 7 m m in
thickness were cut and fixed in 4% paraformaldehyde and stained accord-
ing to the manufacturer’s instructions (Boehringer). This assay measures
DNA strand breaks and is therefore diagnostic for cells undergoing 
apoptosis.
Cell survival assay and adenovirus infection. HT1080V and HT1080I cells
were left untreated or treated with CPT (Sigma) or SN38 (Pharmacia) for 24
h. The surviving cells were stained with 0.05% crystal violet in 20% ethanol.
The dye was eluted and crystal violet staining was quantified at 595 nm
wavelength using a kinetic microplate reader. The ‘super-repressor’ Ik B a
was cloned into the replication-deficient Ad5 vector with transgene expres-
sion driven by the CMV early promoter. The cells were pre-infected with
Ad.CMV.I k B a or Ad.CMV3 empty control vector for 1 h. After 24 h of infec-
tion, the cells were treated with 50 ng/ml TNF for 24 h. The surviving cells
were quantified by the crystal violet assay.
In vivo tumor growth and TNF treatment. HT1080I cells (1 · 106 cells/0.1
ml) or control HT1080V cell suspensions were injected subcutaneously into
each flank of female, athymic, nu/nu mice 5–6 weeks old (Taconic,
Germantown, New York). Tumors were allowed to develop for 21 d and
then were injected with TNF a (10 m g/100 m l in PBS once a day for 3 d). Both
maximum and minimum diameters of resulting tumor were measured over
the skin every 2 days using a slide caliper. At the end of experiments, the tu-
mors were surgically removed under aseptic conditions and weighed. The
tumors were then subjected to histological analysis and TUNEL assays.
Tumor studies with Ad.CMV.Ik B a and CPT-11. Chemosensitization re-
sponses were evaluated in subcutaneous tumors grown in nu/nu mice.
Tumor cells (1 · 106) were injected subcutaneously in the flanks of nu/nu,
female, athymic nude mice 5–6 weeks old (body weight, 18–20 g). Tumors
were treated 2–3 weeks after cancer cells were injected when tumor dimen-
sions were approximately 1 cm · 1 cm. Tumor treatment involved the in-
tratumoral injection of recombinant adenovirus Ad.CMV.Ik B a (ref. 20),
using a described technique43. Virus (1 · 1010 PFU, diluted in a total of 200
m l of PBS) was administered in a single pass of a 27-gauge hypodermic nee-
dle. A second virus injection was given 7 d after the first. The recombinant
adenovirus Ad.CMV3 and vehicle alone were used as controls. CPT-11
(Irinotecan; Pharmacia & Upjohn Company, Kalamazoo, Michigan) was ad-
ministered by tail vein injection at a dose of 33 mg/kg in 100 m l every 4 d
beginning 24 h after the first viral injection. A total of five doses of CPT-11
were given. PBS (100 m l) administered by tail vein injection was used as a
control for drug treatment. Tumor diameter was measured along the
longest orthogonal axes every other day after treatment was initiated, and
recorded as tumor volume. Tumor volume was calculated by assuming a
spherical shape, using the formula (volume = 4/3 p r3), where r = 1/2 (mean
tumor diameter measured in two dimensions).
Tumors were fixed in 10% formalin and embedded in paraffin blocks.
Paraffin-embedded sections were pre-treated with dewax and rehydrated
(55 °C for 15 min), then washed in xylene and rehydrated through a graded
series of ethanol and redistilled water. Tissue sections were then incubated
with proteinase K (20 m g/ m l in 10 mM Tris/HCl, pH 7.4–8.0, for 15 min at
21–37 °C), permeabilized in 0.1% Triton-X100 in 0.1% sodium citrate, and
then labeled with the TUNEL reaction mixture (Boehringer).
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